MORRIS PLAINS, N.J., April 28 /PRNewswire-FirstCall/ -- Immunomedics, Inc.
(Nasdaq: IMMU) today announced that Cynthia L. Sullivan, President and Chief
Executive Officer, will be presenting at the Rodman & Renshaw Techvest 2nd
Annual Global Healthcare Conference scheduled for May 4 - 6, 2005 in Paris,
France.
Ms. Sullivan's presentation, scheduled for Thursday, May 5, 2005 at 10:10
a.m. (4:10 a.m. Eastern Time), will provide a corporate overview, including
comments on the Company's product portfolio. The presentation can be
downloaded simultaneously at
http://www.immunomedics.com/1aboutus/rodmanrenshawparis.pdf .
Immunomedics is a biopharmaceutical company focused on the development of
monoclonal, antibody-based products for the targeted treatment of cancer,
autoimmune and other serious diseases. We have developed a number of advanced
proprietary technologies that allow us to create humanized antibodies that can
be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics or toxins, in each case to create
highly targeted agents. Using these technologies, we have built a pipeline of
therapeutic product candidates that utilize several different mechanisms of
action. We believe that our portfolio of intellectual property, which includes
approximately 90 issued patents in the United States, and more than 250 other
issued patents worldwide, protects our product candidates and technologies.
This release, in addition to historical information, contains forward-
looking statements made pursuant to the Private Securities Litigation Reform
Act of 1995. Such statements, including statements regarding clinical trials,
out-licensing arrangements, and capital raising activities, involve
significant risks and uncertainties and actual results could differ materially
from those expressed or implied herein. Factors that could cause such
differences include, but are not limited to, risks associated with new product
development (including clinical trials outcome and regulatory
requirements/actions), competitive risks to marketed products and availability
of financing and other sources of capital, as well as the risks discussed in
the Company's Annual Report on Form 10-K for the fiscal year ended June 30,
2004. The Company is not under any obligation, and the Company expressly
disclaims any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise.
Company Contact: Chau Cheng, Associate Director, Investor Relations &
Business Analysis, (973) 605-8200, extension 123. Visit the Company's web site
at http://www.immunomedics.com .
SOURCE Immunomedics, Inc.
 back to top
Related links:
http://www.Immunomedics.com
http://www.immunomedics.com/1aboutus/rodmanrenshawparis.pdf
Company News On-Call:
http://www.prnewswire.com/comp/113121.html
CONTACT:
Chau Cheng, Associate Director, Investor
Relations & Business Analysis, Immunomedics, Inc.,
+1-973-605-8200, extension 123
|
